Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Bigginvestoron Apr 28, 2021 1:12pm
179 Views
Post# 33083368

RE:RE:RE:RE:RE:Reverse split is a necessity

RE:RE:RE:RE:RE:Reverse split is a necessity
whisky11 wrote: zardoz00]I have read all of Farell's interviews. I also have experience with RS including from a bio-tech, IN who recently did one to enter NASDAQ.  Even though they had a series of good news and IMO more potential than CLASS, the stock lost about 75% of it's value between july and mid-april. It is just starting to go up following a series of very good news.  So if and only if CLASS gets massive financial plus government support prior to it's RS will I keep my shares before the RS.  JMO and GLTA

whisky11: if we're talking about which Canadian company has more potential,NO is used  on people for a long time to save lives. Somewhere on the company website is posted report from the hospital in United States where they treated pregnant ladies with NO
26 from 26 patients survived coronavirus and 25 of them had successful delivery.
If R-107 works the same way it worked on large animals in the last study then there is no another company with  more potential than Caritas.
R-107 Will be  remedy for any mutation of coronavirus ,common cold and flu included. So if   R-107 behave the same way like it did on dogs This is similar to discovery of antibiotics, Bitcoins or Tesla car. I voiced my opposition to reverse split in order to get the NASDAQ. But in this case it's necessity to be able to attract big guys to invest and to avoid five cents TSX rule .




where is the news release after closing??
<< Previous
Bullboard Posts
Next >>